国药控股港股公告转发子公司国药股份2026年三季报：Q3单季净利同比+9.7%，但前三季净利仍同比-1.07%

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no
responsibility for the contents of this announcement, make no representation as to its accuracy or
completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.




ANNOUNCEMENT
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL
INDICATORS OF SINOPHARM (CNCM LTD)
FOR THE THIRD QUARTER OF 2026
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and
Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the
“Company”) dated 20 October 2026 (the “Announcement”) in relation to the 2026 third
quarterly report of China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司)
(“SINOPHARM (CNCM LTD)”), a subsidiary of the Company and whose A shares are listed
on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and
the public investors to the following principal unaudited accounting data and financial
indicators of SINOPHARM (CNCM LTD) for the third quarter of 2026 as set out in the
Announcement.



* The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF
SINOPHARM (CNCM LTD)
Unit: Yuan
Currency: RMB

Changes of the
Changes of period from the
the From the beginning of
Reporting beginning of the the year to the
Reporting Period Period over year to the end of end of the
the same the Reporting Reporting
period of last Period Period over the
year (%) same period of
last year (%)

Revenue 13,878,085,353.85 0.95 40,606,422,021.73 3.11


Net profit
attributable to 596,464,172.79 9.70 1,476,233,652.87 -1.07
shareholders of the
listed company
Net profit
attributable to
shareholders of the
listed company 595,690,042.65 10.59 1,475,460,390.97 0.36
after deducting
non-recurring
gains and losses
Net cash flow
arising from N/A N/A -2,406,818,944.22 N/A
operating activities
Basic earnings per 0.7906 9.71 1.9566 -1.07
share (Yuan/share)
Diluted earnings
per share 0.7906 9.71 1.9566 -1.07
(Yuan/share)
Weighted average Increased by
Decreased by
return on net 0.06
3.12 7.79 0.71 percentage
assets (%) percentage
point
point




2
Changes of the end
of
At the end of the the Reporting
At the end of last year
Reporting Period Period
over the end of last
year (%)
Total assets 36,813,323,715.90 36,685,023,982.59 0.35

Equity
attributable to
shareholders of 19,408,289,559.64 18,544,719,561.48 4.66
the listed
company

Note: “Reporting Period” refers to the three months ended 30 September 2026.




By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman
Shanghai, the PRC
20 October 2026


As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr.
Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr.
Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the
independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr.
Shi Shenghao and Mr. Chen Weiru.




3